Literature DB >> 16780627

A physical performance measure for individuals with mucopolysaccharidosis type I.

Stephen M Haley1, Maria A Fragala Pinkham, Helene M Dumas, Pengsheng Ni, Alison M Skrinar, Gerald F Cox.   

Abstract

The purpose of this article is threefold: (1) to describe the development, reliability, and validity of a revised physical performance measure for individuals with mucopolysaccharidosis type I (MPS I); (2) to standardize the test on a normal sample; and (3) to compare results from a selected sample of individuals with MPS I with age-based centiles. The MPS Physical Performance Measure (MPS-PPM) is composed of eight timed functional tasks (FT-8) and two endurance tasks with a modified Energy Expenditure Index for comfortable walking (CW) and fast walking (FW) speeds. Age norms were derived from a convenience sample of 150 typically developing children and adolescents (75 males, 75 females; mean age 11y 2mo [SD 4y 5mo]; range 5-22y). Using a Rasch model for speed tests and confirmatory factor analysis, we established the unidimensionality of the FT-8. Interrater reliability of the FT-8 (intraclass correlation [ICC]=0.98) and test-retest reliability of the FT-8 (ICC=0.96), CW (ICC=0.91), and FW (ICC=0.83) were good. Results of the age-based profiles in 10 individuals with MPS I (five males, five females; mean age 14y 2mo [SD 7y 6mo]; range 6-29y) indicate that the amount of time needed to perform functional tasks is severely affected by the disease, and most individuals were at or below the fifth centile for their age. The patterns of limitations in endurance were more varied. These results suggest the utility of using this revised MPS-PPM to identify the extent of limitation in age-expected physical performance. Implications for using the MPS-PPM for monitoring physical performance changes during clinical interventions are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 16780627     DOI: 10.1017/S0012162206001216

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  4 in total

1.  Mucopolysaccharidosis (MPS) Physical Symptom Score: Development, Reliability, and Validity.

Authors:  A Ahmed; K Rudser; A Kunin-Batson; K Delaney; C Whitley; E Shapiro
Journal:  JIMD Rep       Date:  2015-08-25

2.  Changes in gait pattern as assessed by the GAITRite™ walkway system in MPS II patients undergoing enzyme replacement therapy.

Authors:  M Wood; M A Cleary; L Alderson; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2009-03-25       Impact factor: 4.982

Review 3.  Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.

Authors:  Haiyan Nan; Chanbum Park; Sungho Maeng
Journal:  Biomed Res Int       Date:  2020-12-04       Impact factor: 3.411

4.  Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?

Authors:  N Williams; D Challoumas; D M Eastwood
Journal:  J Child Orthop       Date:  2017-08-01       Impact factor: 1.548

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.